DOUBLE-BLIND PILOT TRIAL OF ORAL TOLERIZATION WITH MYELIN ANTIGENS IN MULTIPLE-SCLEROSIS
DOUBLE-BLIND PILOT TRIAL OF ORAL TOLERIZATION WITH MYELIN ANTIGENS IN MULTIPLE-SCLEROSIS
复制标题
DOI：
10.1126/science.7680493
复制
发表时间：
1993-02-26
期刊：
影响因子：
56.9
通讯作者：
HAFLER, DA
中科院分区：
文献类型：
--
作者：
WEINER, HL;MACKIN, GA;HAFLER, DA
多发性硬化症(MS)被认为是一种由识别中枢神经系统髓鞘成分的T淋巴细胞介导的自身免疫性疾病。在一项为期一年的双盲研究中，30名复发-缓解型多发性硬化症患者每天服用牛髓磷脂胶囊或对照蛋白，以确定口服耐受髓鞘抗原对疾病的影响。髓磷脂治疗组15人中有6人至少有一次严重恶化；对照组15人中有12人发作。髓鞘治疗组与髓鞘碱性蛋白反应的T细胞减少。未发现毒副作用。尽管不能从这些数据中得出疗效的结论，但它们为MS和其他自身免疫性疾病开辟了一个研究领域
Multiple sclerosis (MS) is thought to be an autoimmune disease mediated by T lymphocytes that recognize myelin components of the central nervous system. In a 1-year double-blind study, 30 individuals with relapsing-remitting MS received daily capsules of bovine myelin or a control protein to determine the effect of oral tolerization to myelin antigens on the disease. Six of 15 individuals in the myelin-treated group had at least one major exacerbation; 12 of 15 had an attack in the control group. T cells reactive with myelin basic protein were reduced in the myelin-treated group. No toxicity or side effects were noted. Although conclusions about efficacy cannot be drawn from these data, they open an area of investigation for MS and other autoimmune diseases